You searched for "nAMD"

415 results found

RPE tears in cases of IPCV

The aim of this study was to investigate the occurrence, characteristics, management and prognosis of retinal pigment epithelium (RPE) tears in patients with polypoidal choroidal vasculopathy (PCV). Medical records of previous cases were reviewed over an eight-year period from a...

Progression of macular atrophy on long-term anti-VEGF therapy for AMD

This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Specialist high-street eye clinics for managing patients with retinal disorders can enhance care standards

The author examines the successful introduction of community-based retinal clinic services by Manchester University NHS Foundation Trust. Dr Sajjad Mahmood, Consultant Ophthalmologist, MREH, shares experience of establishing community-based medical retina clinic services. Sight loss from age-related macular degeneration (AMD), cataract,...

ABCA1 mediates lipid efflux in the retina

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. There are two forms of AMD, dry and wet, the latter so named because of the presence of choroidal neovascularisation. Both forms lead to retinal pigment...

Stereotactic radiotherapy for polypoidal choroidal vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...

Reduced blood flow and age-related macular degeneration

This was a prospective cross-sectional study assessing changes in blood flow velocity in patients with age-related macular degeneration (AMD) using a retinal function imager. Sixty eyes with wet AMD were compared to 53 control eyes and the average blood flow...

Assessing everyday visual function in dry AMD – what matters to the person?

Age-related macular degeneration (AMD) is the primary cause of blindness in the developed world and is accountable for more than one half of sight impairment registrations within England and Wales [1]. AMD is prevalent in people aged 60 years and...

Telemedicine strategies in ophthalmology: harnessing established and emerging technologies for lasting solutions

The author considers recent progress and shares insights from leading practitioners in telemedicine applications and digital technology strategies. Amidst COVID-19 and combined mitigation and suppression measures, hospitals and clinics have responded rapidly to strengthen telemedicine strategies and virtual healthcare services...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...